Abstract:Background: Gan–Dou–Fu–Mu decoction (GDFMD) improves liver fibrosis in experimental and clinical studies including those on toxic mouse model of Wilson disease (Model). However, the mechanisms underlying the effect of GDFMD have not been characterized. Herein, we deciphered the potential therapeutic targets of GDFMD using transcriptome analysis. Methods: We constructed a tx-j Wilson disease (WD) mouse model, and assessed the effect of GDFMD on the liver of model mice by hematoxylin and eosin, Masson, and immunohistochemical staining. Subsequently, we identified differentially expressed genes (DEGs) that were upregulated in the Model (Model vs. control) and those that were downregulated upon GDFMD treatment (compared to the Model) using RNA-sequencing (RNA-Seq). Biological functions and signaling pathways in which the DEGs were involved were determined by gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) pathway analyses. A protein–protein interaction (PPI) network was constructed using the STRING database, and the modules were identified using MCODE plugin with the Cytoscape software. Several genes identified in the RNA-Seq analysis were validated by real-time quantitative PCR. Results: Total of 2124 DEGs were screened through the Model vs. control and Model vs. GDFMD comparisons, and dozens of GO and KEGG pathway terms modulated by GDFMD were identified. Dozens of pathways involved in metabolism (including metabolic processes for organic acids, carboxylic acids, monocarboxylic acids, lipids, fatty acids, cellular lipids, steroids, alcohols, eicosanoids, long-chain fatty acids), immune and inflammatory response (such as complement and coagulation cascades, cytokine–cytokine receptor interaction, inflammatory mediator regulation of TRP channels, antigen processing and presentation, T-cell receptor signaling pathway), liver fibrosis (such as ECM-receptor interactions), and cell death (PI3K-Akt signaling pathway, apoptosis, TGF-beta signaling pathway, etc.) were identified as potential targets of GDFMD in the Model. Some hub genes and four modules were identified in the PPI network. The results of real-time quantitative PCR analysis were consistent with those of RNA-Seq analysis. Conclusions: We performed gene expression profiling of GDFMD-treated WD model mice using RNA-Seq analysis and found the genes, pathways, and processes effected by the treatment. Our study provides a theoretical basis to prevent liver fibrosis resulting from WD using GDFMD.

Exploring the impact of gut microbiota on liver health in mice and patients with Wilson disease

Multi-omics study unravels gut microbiota and metabolites alteration in patients with Wilson's disease

Does Gut Microbiome have an Effect on Wilson’s Disease Phenotype?

Western Diet Aggravated Carbon Tetrachloride-Induced Chronic Liver Injury by Disturbing Gut Microbiota and Bile Acid Metabolism.

Vital Members in the Gut Microbiotas Altered by Two Probiotic Bifidobacterium Strains Against Liver Damage in Rats

Metabolomic and biochemical changes in the plasma and liver of toxic milk mice model of Wilson disease

Disorganized Gut Microbiome Contributed to Liver Cirrhosis Progression: A Meta-Omics-Based Study

Distinctly Altered Gut Microbiota In The Progression Of Liver Disease

Wangshi Baochi Pills Alleviate Alcoholic Liver Disease by Regulating the Gut Microbiota Composition in a Mouse Model

Changes and Correlations of the Intestinal Flora and Liver Metabolite Profiles in Mice With Gallstones

Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality.

Multi-Omics Analysis of the Gut-Liver Axis Reveals the Mechanism of Liver Injury in Colitis Mice

Aberrant copper metabolism and hepatic inflammation cause neurological manifestations in a mouse model of Wilson's disease

Longitudinal gut fungal alterations and potential fungal biomarkers for the progression of primary liver disease

Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases

Exploration of TCM syndrome types of the material basis and risk prediction of Wilson disease liver fibrosis based on 1H NMR metabolomics

Comprehensive RNA-Seq Analysis of Potential Therapeutic Targets of Gan–Dou–Fu–Mu Decoction for Treatment of Wilson Disease Using a Toxic Milk Mouse Model

Bile acid-gut microbiota imbalance in cholestasis and its long-term effect in mice

The Role of Gut Microbiota in Mice with Bile Duct Ligation-Evoked Cholestatic Liver Disease-Related Cognitive Dysfunction

Metabolomic Profiling of Wilson Disease, an Inherited Disorder of Copper Metabolism, and Diseases with Similar Symptoms but Normal Copper Metabolism

Gut Microbiota and Metabolomics Correlation in a Mouse Model of Acute-on-Chronic Liver Failure